Key regions: Australia, Germany, United Kingdom, United States, France
The use of immunosuppressants in healthcare has been on the rise in recent years, and Northern Africa is no exception.
Customer preferences: Patients in Northern Africa suffering from autoimmune diseases, such as rheumatoid arthritis and lupus, have been increasingly turning to immunosuppressants to manage their conditions. This is due to the effectiveness of these drugs in suppressing the immune system, which can help alleviate symptoms and prevent further damage to the body.
Trends in the market: The immunosuppressants market in Northern Africa has been experiencing steady growth in recent years, with an increasing number of pharmaceutical companies entering the market. This has led to greater competition and a wider range of options for patients. Additionally, the market has seen a shift towards the use of biosimilars, which are cheaper alternatives to branded drugs. This has made immunosuppressants more accessible to patients in the region.
Local special circumstances: One of the main challenges facing the immunosuppressants market in Northern Africa is the lack of access to healthcare in some areas. This can make it difficult for patients to receive the treatment they need, especially those living in rural areas. Additionally, there is a lack of awareness and education surrounding autoimmune diseases and their treatment, which can lead to a delay in diagnosis and treatment.
Underlying macroeconomic factors: The healthcare industry in Northern Africa is undergoing significant growth, driven by increasing investment in healthcare infrastructure and rising demand for healthcare services. This has led to an increase in the availability of immunosuppressants, as well as other pharmaceuticals, in the region. Additionally, the growing middle class in countries such as Egypt and Morocco has led to an increase in healthcare spending, which has further fueled the growth of the immunosuppressants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
